Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter, randomized, double-blind, parallel group comparative study by intramuscularly administering to patients with spasmodic torticollis. Primary endpoint for efficacy evaluation is changes in TWSTRS total scores from baseline measured at Week 4 and the clinical recommended dose will be examined with Williams multiple comparison. For safety evaluation, an inter group comparison (active drug and placebo) will be performed mainly focusing on incidence of adverse events, adverse drug reactions, and abnormal changes in laboratory parameters.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BOTULINUM TOXIN TYPE B | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment | The TWSTRS-Total score is the sum of scores of the three components of the scale:
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | Baseline, Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in Patient Global Assessment - Visual Analog Scale (PtGA-VAS) at Week 4 After Treatment | Change from Baseline in PtGA-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. Participants answered: "Considering all the ways your cervical dystonia affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients who are botulinum toxin-resistant in previous exposures (primary no-responder*)
*If patients who were once responder to botulinum toxin treatment but thereafter became non-responder can be included in this study.
Patients whose passive range of motion in the neck is significantly narrowed due to cervical contracture or spondylosis.
Patients having only pure retrocollis- or anterocollis-associated symptoms.
Patients who received botulinum toxin agents within 4 months prior to study treatment of E2014, or those who show carry-over effect of previous treatment with botulinum toxin at the time of starting study administration even though the previous treatment was given 4 months or earlier.
Patients who were treated with narcotics or antibiotics that may potentiate effects of muscle relaxation (spectinomycin hydrochloride preparations, aminoglycosides, polypeptides, tetracyclines, lincomycins) within 4 months prior to study treatment.
Patients who started or altered the dose levels of the following agents (musculoskeletal relaxants, antispasm drugs, strong tranquilizers, benzodiazepines including similar drugs, anticholinergic drugs, antiparkinsonian drugs, antidepressants) within 4 weeks prior to study treatment.
Patients who received medical care(s) other than pharmacotherapies (surgical interventions, MAB, acupuncture, relaxation, etc.) prior to study treatment showing carry-over effect of these cares or unstable condition at the time of starting study treatment.
Patients who have a history of myectomy or neurectomy in the neck and/or shoulder.
Patients who have a history of hypersensitivity to E2014's ingredients (botulinum toxin type B, human serum albumin, sodium succinate buffer solution), or other type of botulinum toxins.
Patients with complication(s) or history of serious neurological or musculoskeletal disease (myasthenia, amyotrophic lateral sclerosis, etc.), cardiovascular disease (acute myocardial infarction, etc.), respiratory disease (COPD, etc.), renal disease (acute or chronic renal failure, etc.), hepatic disease (cirrhosis, etc.), gastrointestinal disease (paralytic ileus, etc.), dermatological disease (toxic epidermal necrosis, etc.), psychiatric disease (schizophrenia, alcohol or drug dependence, etc.), hematological disease (aplastic anemia, etc.), and/or infectious disease (hepatitis, syphilis, AIDS, etc.).
Patients with complication or history of malignant tumor(s).
Patients who participated in another clinical study within 30 days prior to obtaining informed consent for this study.
Women of pregnant, childbearing potential, childbearing intension during the study period, or lactating.
Others who are judged to be ineligible for study entry by the investigator or subinvestigator
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ichihara | Chiba | 290-0003 | Japan | |||
Not provided
130 patients (33 of the placebo group, 34 of the 2500U group, 32 of the 5000U group, and 31 of the 10000U group) received study treatment, but after randomization, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose |
| FG001 | E2014 2,500 U | 2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, Week 4 |
| Mean Change From Baseline in Physician Global Assessment Disease Assessment - Visual Analog Scale (PGA-VAS) at Week 4 After Treatment | Change from Baseline in PGA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. | Baseline, Week 4 |
| Mean Change From Baseline in the TWSTRS - Functional Disability Score at Week 4 After Treatment | TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | Baseline, Week 4 |
| Mean Change From Baseline in the TWSTRS - Pain Score at Week 4 After Treatment | TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | Baseline, Week 4 |
| Mean Change From Baseline in the TWSTRS - Severity Score at Week 4 After Treatment | TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | Baseline, Week 4 |
| Mean Change From Baseline in Patient Pain Assessment (VAS) at Week 4 After Treatment | Change from Baseline in Patient's Pain Assessment-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. The patient's assessment of pain was performed using a 100 mm VAS)ranging from no pain (0) to unbearable pain (100). The distance in mm from the left edge of the scale was measured. A negative change from Baseline score indicates improvement in pain intensity. | Baseline, Week 4 |
| Kitakyushu |
| Fukuoka |
| 807-0804 |
| Japan |
| Sapporo | Hokkaido | 060-0061 | Japan |
| Sapporo | Hokkaido | 060-0814 | Japan |
| Kagoshima | Kagoshima-ken | 890-0075 | Japan |
| Kawasaki | Kanagawa | 216-0015 | Japan |
| Sagamihara | Kanagawa | 228-0829 | Japan |
| Kyoto | Kyoto | 601-1434 | Japan |
| Matsumoto | Nagano | 390-0802 | Japan |
| Kashihara | Nara | 634-0813 | Japan |
| Moriguchi | Osaka | 570-0074 | Japan |
| Osaka | Osaka | 553-0003 | Japan |
| Sakai | Osaka | 590-0132 | Japan |
| Saitama | Saitama | 338-0002 | Japan |
| Saitama | Saitama | 338-0003 | Japan |
| Tokorozawa | Saitama | 359-1141 | Japan |
| Hamamatsu | Shizuoka | 430-0906 | Japan |
| Tokushima | Tokushima | 770-0042 | Japan |
| Bunkyo-ku | Tokyo | 113-0033 | Japan |
| Meguro-ku | Tokyo | 153-0044 | Japan |
| Shinjuku-ku | Tokyo | 162-0054 | Japan |
| FG002 | E2014 5,000 U | 5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
| FG003 | E2014 10,000 U | 10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
| COMPLETED |
|
| NOT COMPLETED |
|
|
After randomized to the treatment groups, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose. Two subjects from the placebo group did not receive treatment after randomization. |
| BG001 | E2014 2,500 U | 2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
| BG002 | E2014 5,000 U | 5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose. One subject from the 5,000 U/2 mL did not receive treatment after randomization. |
| BG003 | E2014 10,000 U | 10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary | Mean Change From Baseline in Patient Global Assessment - Visual Analog Scale (PtGA-VAS) at Week 4 After Treatment | Change from Baseline in PtGA-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. Participants answered: "Considering all the ways your cervical dystonia affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. | FAS | Posted | Mean | Standard Error | Millimeters | Baseline, Week 4 |
|
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Physician Global Assessment Disease Assessment - Visual Analog Scale (PGA-VAS) at Week 4 After Treatment | Change from Baseline in PGA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. | FAS | Posted | Mean | Standard Error | Millimeters | Baseline, Week 4 |
| ||||||||||||||||||||||||||||||||||||
| Primary | Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment | The TWSTRS-Total score is the sum of scores of the three components of the scale:
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | Full Analysis Set (FAS) population: All subjects who received study treatment | Posted | Mean | Standard Error | Points on a Scale | Baseline, Week 4 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the TWSTRS - Functional Disability Score at Week 4 After Treatment | TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | FAS | Posted | Mean | Standard Error | Points on a Scale | Baseline, Week 4 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the TWSTRS - Pain Score at Week 4 After Treatment | TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | FAS | Posted | Mean | Standard Error | Points on a Scale | Baseline, Week 4 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the TWSTRS - Severity Score at Week 4 After Treatment | TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score. | FAS | Posted | Mean | Standard Error | Points on a Scale | Baseline, Week 4 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Patient Pain Assessment (VAS) at Week 4 After Treatment | Change from Baseline in Patient's Pain Assessment-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. The patient's assessment of pain was performed using a 100 mm VAS)ranging from no pain (0) to unbearable pain (100). The distance in mm from the left edge of the scale was measured. A negative change from Baseline score indicates improvement in pain intensity. | FAS | Posted | Mean | Standard Error | Millimeters | Baseline, Week 4 |
|
Baseline to last observation carried forward
130 patients (33 of the placebo group, 34 of the 2500U group, 32 of the 5000U group, and 31 of the 10000U group) received study treatment, but after randomization, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose | 0 | 33 | 9 | 33 | ||
| EG001 | E2014 2,500 U | 2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose | 0 | 34 | 3 | 34 | ||
| EG002 | E2014 5,000 U | 5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose | 0 | 32 | 4 | 32 | ||
| EG003 | E2014 10,000 U | 10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose | 2 | 31 | 7 | 31 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cataract | Eye disorders | MedDRA | Systematic Assessment |
| |
| Pelvic Fracture | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Thirst | General disorders | MedDRA | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Injection Site Pain | General disorders | MedDRA | Systematic Assessment |
| |
| Blood Creatine Phosphokinase Increased | Investigations | MedDRA | Systematic Assessment |
| |
| Dry Mouth | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Glucose Urine Present | Investigations | MedDRA | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Hiroki Shimizu, Study Director | Eisai Co., Ltd. | +81-3-3817-5245 |
| ID | Term |
|---|---|
| D014103 | Torticollis |
| ID | Term |
|---|---|
| D004421 | Dystonia |
| D020820 | Dyskinesias |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C096323 | rimabotulinumtoxinB |
Not provided
Not provided
Not provided
| 40 to less than 60 years |
|
| Greater than or equal to 60 years |
|
| Male |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| OG003 |
| E2014 10,000 U |
10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|